Modified non-natural NKG2D ligands that selectively deliver attached heterologous molecules to non-natural NKG2D receptors on car-cells

US11440948B2 · kind B2 · utility

Assignees

• XYPHOS BIOSCIENCES INC. · US
• THE J. DAVID GLADSTONE INSTITUTES · US

Inventors

• Kaman Kim · South San Francisco, US
• Nigel Killeen · San Francisco, US
• Eytan Herzig · South San Francisco, US
• Warner C. Greene · Chapel Hill, US

Key dates

• Filing date: Jan 28, 2020
• Grant date: Sep 13, 2022
• Expiry date: Feb 3, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/33
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This application relates generally to the production of modified, non-natural α1-α2 domains of NKG2D ligands with attached polypeptides having specific target-binding properties, for example, antibodies or variable fragments of antibodies, that are selectively delivered to Chimeric Antigen Receptors (CARs) comprised of modified, non-natural NKG2D receptors on engineered mammalian cells. The targeting of surface-expressed molecules includes those of virus-infected cells that can then be attacked and ablated by engineered cells of the immunity system expressing CARs cognate to the modified, non-natural α1-α2 domains of NKG2D ligands with attached polypeptides.